



Nexstim

Targeting a paradigm shift in stroke rehabilitation

Martin Jamieson | CEO & Chairman of the Board | Nexstim

Mikko Karvinen | CFO | Nexstim

Biotech and Money Inv€\$tival, London, 18 November 2016

 @NexstimOyj

Important information

This document and the information contained herein are being presented by Nexstim Oyj (“Nexstim” or the “Company”). In connection with any presentation or review of this document, you agree to be bound by the following limitations and notifications.

This document and the information contained herein are being provided to you solely for your information. The distribution of this document in some jurisdictions may be restricted by law and persons into whose possession this document comes are required to inform themselves about and observe any such restrictions. Accordingly, this document may not be distributed in any jurisdiction except under circumstances that will result in compliance with applicable laws and regulations.

This document is not a prospectus, and the information contained herein does not and is not intended to constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of any securities in connection with this document in any jurisdiction. This document and the information contained herein are not an offer of securities in the United States and are not for distribution in the United States.

Recipients should not treat the contents of the document as advice relating to legal, taxation or other matters. This presentation does not purport to be all-inclusive or to contain any or all the information that prospective investors may desire in analysing and deciding whether or not to hold or transact in the Company’s shares. Neither the Company nor any of its affiliates or representatives makes any representation or warranty, express or implied, as to the accuracy or completeness of this document or any of the information contained herein, or any other written or oral communication transmitted or made available to the recipient or its affiliates or representatives. The Company and its affiliates or representatives expressly disclaim to the fullest extent permitted by law any and all liability based, in whole or in part, on this document or any information contained herein or any other written or oral communication transmitted or made available to the recipient or its affiliates or representatives, including, without limitation, with respect to errors therein or omissions therefrom.

Recipients should not assume that the information in this document is accurate as of any date other than the date of this presentation. Nothing contained herein is, or should be relied upon as, a promise or representation as to future performance. The Company does not undertake any obligation to update or revise this this document.

Certain of the information contained herein concerning industry and market data, economic trends, market position and competitiveness is based upon or derived from information provided by third-party consultants and other industry sources. Neither the Company nor any of its affiliates or representatives can guarantee the accuracy of such information or has independently verified the assumptions upon which projections of future trends and performance in such information are based.

Nexstim's NBS System is cleared by the FDA for assessment of the motor and speech cortices for pre-procedural planning. The NBT System is not cleared for commercial distribution in the United States.

FORWARD-LOOKING STATEMENTS

This document may contain forward-looking statements that reflect the Company’s current views with respect to certain future events and potential financial performance. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will materialise. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors. To the extent that this document contains opinions, estimates, forecasts or other forward looking statements, no guarantees or undertakings that these are correct or complete are given by the Company or any of its respective members, advisors, officers or employees or any other person. Forecasts and assumptions which are subject to economic and competitive uncertainty are outside such person’s control and no guarantee can be given that projected results will be achieved or that outcomes will correspond with forecasts. Information in this document may be changed, added to or corrected without advance notification.

Nexstim Plc at a Glance

- Finnish medtech
- Established in 2000
- Offices in Finland, US and Germany
- Backed by leading European life-science VCs
- Listed in Nasdaq First North Finland & Sweden



NBS Pre-Surgical Mapping Overview

- Maps the Motor and Speech Cortex prior to tumour surgery
- Application in epilepsy
- The NBS system links
 - Brain anatomy (MRI)
 - Location of the TMS (navigation)
 - Muscle response (EMG)
- Navigation is the key – NBS system visualizes the precise area of the brain that is affected



NBS vs. Direct Cortical Stimulation (DCS) motor mapping

Nexstim's NBS

Nexstim



Non-invasive

Mapping possible days or weeks prior to surgery

DCS - Current "gold standard"




Invasive

Mapping during surgery

NBS Pre-Surgical Mapping makes the difference to clinical outcome

Progression-free Survival (Months)




¹ Dietmar Frey, Peter Vajkoczy, and Thomas Picht **Navigated transcranial magnetic stimulation improves the treatment outcome in patients with brain tumors in motor eloquent locations** Neuro Oncology 2014 : nou110v1-nou110

NBS Pre-Surgical Mapping Major Centers




NBT[®] (Navigated Brain Therapy) has potential for multiple therapeutic applications due to precise navigation




Market opportunity in stroke rehabilitation


2015 Incidence of stroke



2025 Incidence of stroke



2015 Stroke survivors



*Published data

- Target patients with upper limb paralysis
- Focus on the period over 3 months post stroke

Status of Regulatory Development for Stroke

- CE mark for stroke rehabilitation
- Nexstim submitted 510(k) De Novo documentation to the FDA based on the clinical data in June 2016
- The Pre-submission includes full data from a total of 173 patients from the Phase III multi-centre clinical trial. Positive data from the control group explained by active sham coil
- Feedback meeting with FDA September 14th, 2016
 - Agreed to a limited size supplementary trial
 - Trial protocol submitted in October 2016 and estimated trial design approval by the FDA late 2016 to early 2017
 - An established financing plan is in place for supporting trial

Nexstim Funding

- Agreed a two year funding arrangement with Bracknor Investment and Finnish Innovation Fund Sitra
- Funding arrangement is a combination of:
 - EUR 5 million of convertible bonds
 - EUR 6.5 million stand-by equity facilities
 - EUR 0.5 million direct share issue
 - EUR 5 million warrants
- Costs aligned to therapy strategy, targeting annual savings of EUR 2.3 million





Nexstim

Thank you